Remove 2009 Remove DNA Remove Therapies
article thumbnail

Gene Therapy Shows No Long-Term Harm in Animals: Study

The Pharma Data

11, 2020 — Results from a long-term study of a gene therapy technique to prevent inherited mitochondrial disease show promise, researchers say. The researchers said the technique could break the cycle of disease passed from mother to baby through mutations in mitochondrial DNA (mtDNA). FRIDAY, Dec. in the small intestine.

article thumbnail

ViiV Healthcare Announces Analysis Showing no Antiretroviral Therapy Interruptions Due to COVID-19 Across its Clinical Development Programme for Investigational, Long-Acting Cabotegravir and Rilpivirine

The Pharma Data

In the midst of the global pandemic, the analysis found no antiretroviral therapy interruptions across the entirety of the ongoing clinical development programme for long-acting cabotegravir and rilpivirine. Of those participants who transitioned back to injectables, the median duration of oral therapy was 51 days.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Precision Medicine in the Genomic Era

DrugBank

Their use, as well as their integration into other types of data, has enabled the development of more precise therapies. In contrast, non-coding mutations have effects on gene expression, transcript stability, and the physical state of the DNA itself (e.g., 5 , e1000433 (2009). PLoS Genet.  Kennedy, A. Ozbek, U. &

Disease 98
article thumbnail

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

The Pharma Data

The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).

article thumbnail

New Drug Miplyffa Approved for Rare Niemann-Pick Disease Type 3

PLOS: DNA Science

The new drug is taken with miglustat , which FDA approved for use in NPD3 in 2009. Until today, there were no approved therapies in the US. The post New Drug Miplyffa Approved for Rare Niemann-Pick Disease Type 3 appeared first on DNA Science. The original approved was in 2003 to treat a type of Gaucher disease.

Disease 52
article thumbnail

Codon Digest: CAR-T Therapy for Neuroblastoma

Codon

” — Harold Morowitz 🔥 Ten Amazing Things (that happened this week…) A CAR-T therapy was tested in 27 children with neuroblastomas. Thousands of transcription factors — proteins that bind DNA and control gene expression — were studied in human cells. Molecular Therapy. Gene Therapy.

article thumbnail

Raising Welfare for Lab Rodents

Codon

As the biotechnologist Alex Telford writes , “Without mouse models, we may never have developed polio and meningitis vaccines, organ transplants, GLP-1 drugs, gene therapies , or any other number of transformative treatments.” In 1959, before DNA sequencing, temperamentally-wild foxes used in the fur trade were bred for tameness.

Research 122